Proteomic Analysis of Low-Grade Serous Ovarian Cancer and Comparing It with Non-cancerous Ovarian

被引:1
|
作者
Bashizadeh Fakhar H. [1 ]
Rezaie-Tavirani M. [1 ]
Zali H. [2 ]
Darkhaneh R.F. [3 ]
Nejad E.K. [4 ]
Aghazadeh M.H. [5 ]
机构
[1] Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran
[2] Proteomics Research Center, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran
[3] Department of Obstetrics and Gynecology, Reproductive Health Research Center, Guilan University of Medical Sciences, Rasht, Guilan
[4] Department of Biostatistics, Guilan Road Truma Research Center, Guilan University of Medical Sciences, Rasht
[5] Azad Medical University, Tehran
关键词
Comparison; Low-grade serous ovarian cancer; Non-cancerous ovarian; Proteomics;
D O I
10.1007/s40944-018-0187-8
中图分类号
学科分类号
摘要
Background: In Iran, ovarian cancer is the eighth most common cancer. Serous is considered as the most common of all ovarian cancers. It is usually deadly due to late diagnosis. Moreover, as all studies so far have considered metastatic or high-stage ovarian cancer, this study sought low-grade ovarian serous in human, which is of high importance and aimed at obtaining protein biomarkers that may be useful in diagnosis and treatment of ovarian serous cancer. Materials and Methods: In this experimental study, ten patients with proved low-grade serous ovarian cancer and ten women without ovarian cancer, healthy, and cancerous tissue samples were obtained to perform proteomics. All tissue proteins were purified using standard separation methods, and proteins were separated using two-dimensional electrophoresis. Healthy and tumorous tissue proteomes were compared, and the extent of protein expression was analyzed. Results: This study identified 212 proteins, 41 of which had changes in protein expression in cancer state. The expression of eight proteins was suppressed, and five proteins were expressed in cancerous group. Thirteen proteins in cancer sample showed increase in expression and 15 proteins reduced expression in cancerous tissue. Conclusion: It seems that in this disease, the expression of a large number of proteins in cancerous tissues changed, most of them decreased or not expressed at all. These changed proteins can be effective as biomarker in diagnosis and treatment of this disease. © 2018, Association of Gynecologic Oncologists of India.
引用
下载
收藏
相关论文
共 50 条
  • [21] Identifying mechanisms of therapeutic resistance in low-grade serous ovarian cancer
    Nobre, Silvana Pedra
    Peplinski, Rebekah
    Schillo, Jacob
    Ulmer, Keely
    Riordan, Jesse
    Dupuy, Adam
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S305 - S305
  • [23] Advances in precision therapy of low-grade serous ovarian cancer: A review
    Wang, Qing
    Cao, Sheng-Han
    Li, Yan-Yu
    Zhang, Jing-Bo
    Yang, Xin-Hui
    Zhang, Bei
    MEDICINE, 2024, 103 (17) : E34306
  • [24] Stage I low-grade serous ovarian cancer: Is there a benefit to chemotherapy?
    Vue, Nujsaubnusi
    Horne, Zachary
    Crafton, Sarah
    Krivak, Thomas
    Miller, Eirwen
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S286 - S286
  • [25] Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer
    Karacin, Cengiz
    Sunar, Veli
    Urakci, Zuhat
    Yilmaz, Ali
    Ayhan, Murat
    Ersoy, Mustafa
    Guven, Deniz Can
    Erturk, Ismail
    Durmus, Yasin
    Karacin, Pinar
    Boran, Nurettin
    Ustun, Yaprak Engin
    Meydan, Mutlu
    Dogan, Mutlu
    Oksuzoglu, Berna
    Ates, Ozturk
    Karaca, Mustafa
    Uncu, Dogan
    Ergun, Yakup
    Arik, Zafer
    FUTURE ONCOLOGY, 2024, 20 (04) : 207 - 214
  • [26] New therapeutic opportunities for women with low-grade serous ovarian cancer
    Moujaber, Tania
    Balleine, Rosemary L.
    Gao, Bo
    Madsen, Ida
    Harnett, Paul R.
    DeFazio, Anna
    ENDOCRINE-RELATED CANCER, 2022, 29 (01) : R1 - R16
  • [27] The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer
    Crane, Erin K.
    Sun, Charlotte C.
    Ramirez, Pedro T.
    Schmeler, Kathleen M.
    Malpica, Anais
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2015, 136 (01) : 25 - 29
  • [28] The tuba origin of low-grade serous ovarian carcinoma
    Kong, Beihua
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 : S74 - S74
  • [29] Targeted Therapies in Low-Grade Serous Ovarian Cancers
    Gonzalez, Anna
    Nagel, Christa I.
    Haight, Paulina J.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (07) : 854 - 868
  • [30] Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
    Sadlecki, Pawel
    Grzanka, Dariusz
    Grabiec, Marek
    DISEASE MARKERS, 2018, 2018